Form 4: Edwards Lifesciences Executive Lippis Daniel J. Reports Stock Transactions

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reports the acquisition and disposal of company stock under a pre-arranged trading plan.

Summary

• On April 8, 2025, Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reported transactions involving Edwards Lifesciences Corp [EW] common stock.
• These transactions included the acquisition of 300 shares at $45.2767 and the disposal of 300 shares at $70.61.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 11, 2023.
• Following these transactions, Lippis directly owns 22,863.1066 shares of common stock.
• Lippis also exercised an employee stock option to acquire 300 shares at $45.2767.
• After the reported transactions, Lippis holds options for 330 shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders, providing transparency into their trading activities. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding the trading activities of a key executive.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transactions, Edwards Lifesciences, Lippis Daniel J., Rule 10b5-1, Executive Compensation, Insider Trading